Biotech · Public company · New York, NY, US

Dianthus Therapeutics, Inc.

Ticker DNTH · SEC CIK 0001690585

Track this companyFree. Adds Dianthus Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials44 recruiting or active

Pipeline programs3From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline3

ClaseprubartPhase 3 · Chronic Inflammatory Demyelinating PolyneuropathyClinicalTrials.gov · fetched Nov 12, 2026
ClaseprubartPhase 3 · Myasthenia Gravis, GeneralizedClinicalTrials.gov · fetched Nov 12, 2026
ClaseprubartPhase 2 · Multifocal Motor NeuropathyClinicalTrials.gov · fetched Nov 12, 2026

A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)PHASE3 · RECRUITING · started Jun 29, 2026ClinicalTrials.gov NCT07647510 · fetched Nov 12, 2026
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)PHASE3 · RECRUITING · started Feb 10, 2025ClinicalTrials.gov NCT06858579 · fetched Nov 12, 2026
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor NeuropathyPHASE2 · ACTIVE_NOT_RECRUITING · started Sep 17, 2024ClinicalTrials.gov NCT06537999 · fetched Nov 12, 2026
A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)PHASE2 · ACTIVE_NOT_RECRUITING · started Feb 23, 2024ClinicalTrials.gov NCT06282159 · fetched Nov 12, 2026